please share a diagram showing mechanism of action of Avlayah

Checking Date & Time

Reading File

Searching the Web

Avlayah drug mechanism of action

Finding Sources

Searching Images

tividenofusp alfa Hunter syndrome MPS II mechanism of action enzyme replacement therapy blood brain barrier

Searching the Web

tividenofusp alfa Avlayah mechanism of action IDS enzyme BBB transferrin receptor diagram

Finding Sources

Generating Image

Medical mechanism of action diagram for Avlayah (tividenofusp alfa) for Hunter syndrome (MPS II). The diagram shows: 1) IV infusion of the drug into the bloodstream. 2) The drug structure: IDS enzyme fused to an Fc fragment that binds transferrin receptor (TfR1). 3) At the blood-brain barrier: the Fc binds TfR1 on brain endothelial cells, triggering receptor-mediated transcytosis, transporting the enzyme across the BBB into the CNS. 4) In peripheral tissues and CNS neurons/glial cells: the drug is internalized via mannose-6-phosphate receptor (M6PR) on cell surfaces, trafficked into lysosomes. 5) Inside the lysosome: IDS enzyme cleaves accumulated heparan sulfate and dermatan sulfate (glycosaminoglycans/GAGs), breaking down toxic substrate. 6) Result: reduction of GAG accumulation in both peripheral organs and the brain, alleviating neurological and somatic symptoms of Hunter syndrome. Clean scientific illustration style with labeled arrows and compartments (bloodstream, BBB endothelium, CNS, lysosome).

what cause MDR Hiv?

Checking Date & Time

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

I have comprehensive information to give a thorough answer. Here it is:

Causes of Multidrug-Resistant (MDR) HIV

MDR HIV arises from a combination of intrinsic viral biology and external (host/treatment) factors. The key causes are:

1. Error-Prone Reverse Transcriptase (The Core Driver)

HIV's reverse transcriptase (RT) lacks proofreading activity (unlike cellular DNA polymerases). This results in a mutation rate of approximately 3 × 10⁻⁵ per nucleotide per replication cycle. Combined with HIV's massive replication rate — generating 10⁹ to 10¹⁰ virions per day — this means millions of mutant variants (called quasi-species) are produced daily within a single infected individual. Any mutation that confers drug resistance will be positively selected under drug pressure.

— Janeway's Immunobiology, 10e

2. Pre-existing Resistant Variants (Before Treatment Begins)

Because of the enormous number of daily variants, resistant mutants pre-exist in the viral population even before any drug is given. Estimates indicate that variants with single resistance mutations to individual antiretroviral agents are already present at the start of therapy. When a drug is introduced, it simply selects for these pre-existing mutants.

— Goldman-Cecil Medicine

3. Sequential or Inadequate Monotherapy

Using single drugs or suboptimal regimens is a major driver of MDR:

Resistance to some protease inhibitors requires only a single mutation — resistance emerges within days of starting monotherapy
Resistance to some RT inhibitors also develops rapidly with monotherapy
Resistance to zidovudine (AZT) takes months, as it requires 3–4 mutations in RT simultaneously

The chart below illustrates how fast resistance emerges under monotherapy with a protease inhibitor:

Fig. 13.47 — Resistance of HIV to protease inhibitors develops rapidly. After a single protease inhibitor is given, viral RNA falls sharply, CD4 counts rise briefly, but by week 4 nearly 100% of circulating virus is the drug-resistant mutant.

— Janeway's Immunobiology, 10e, Fig. 13.47

4. Poor Adherence to ART

Subtherapeutic drug levels due to missed doses or incomplete adherence allow viral replication to continue in the presence of drugs — the ideal conditions for selecting resistant mutants. The emergence of resistance is proportional to the frequency of pre-existing variants and their growth advantage under drug pressure.

— Sherris & Ryan's Medical Microbiology, 8e

5. Transmitted (Primary) Resistance

MDR HIV can be acquired directly from another person who is already infected with resistant strains. This is called transmitted drug resistance — a patient may be treatment-naive but already carry MDR virus. This is why HIV genotyping is performed before initiating ART.

6. Accumulation of Resistance Mutations Across Drug Classes

With repeated treatment failures or sequential regimen changes, the virus accumulates mutations targeting multiple drug classes simultaneously:

Drug Class	Key Resistance Mutations
NRTIs (e.g., AZT, 3TC)	M184V, K65R, thymidine analog mutations (TAMs)
NNRTIs (e.g., efavirenz)	K103N, Y181C (single mutation often sufficient)
Protease Inhibitors	Multiple active-site mutations (accumulate stepwise)
Integrase Inhibitors	N155H, Q148H/R/K, G140S

Why HAART/cART Prevents MDR

Combination antiretroviral therapy (cART/HAART) targets multiple enzymes simultaneously. The probability of simultaneous resistance mutations across all targeted proteins is virtually nil — making full MDR extremely unlikely when the patient is fully adherent to a well-chosen regimen.

"It is more difficult for HIV to develop resistance to multiple drugs with multiple target enzymes. Multidrug-resistant HIV strains are likely to be much weaker than the parent strains." — Medical Microbiology, 9e

Summary of Causes

Cause	Mechanism
Error-prone RT (no proofreading)	High baseline mutation rate
Massive viral replication	10⁹–10¹⁰ virions/day → quasi-species swarm
Pre-existing resistant variants	Selected under drug pressure
Monotherapy / inadequate regimens	Single-target drugs easily overcome
Poor adherence	Subtherapeutic levels allow replication + selection
Transmitted resistance	Acquired from a partner with MDR HIV
Sequential regimen changes	Accumulation of multi-class resistance mutations

why NRTI are prone to resistance?

Finding Sources

Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.

This is a shared conversation. Sign in to Orris to start your own chat.